<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 14 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:CMBX12;
panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:CMR17;
panose-1:0 0 0 0 0 0 0 0 0 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.EmailStyle17
{mso-style-type:personal;
color:#1F497D;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-US link=blue vlink=purple><div class=WordSection1><p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span style='font-size:14.0pt;font-family:"Calibri","sans-serif"'>Doctoral Defense<o:p></o:p></span></b></p><p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span style='font-size:14.0pt;font-family:"Calibri","sans-serif"'>Radiation Therapy Optimization:<o:p></o:p></span></p><p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span style='font-size:14.0pt;font-family:"Calibri","sans-serif"'>Uncertainties and Biological Effects<o:p></o:p></span></p><p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Maryam Zaghian<o:p></o:p></span></p><p class=MsoNormal style='text-autospace:none'><b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Advisor:</span></b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'> Dr. Gino Lim<o:p></o:p></span></p><p class=MsoNormal style='text-autospace:none'><b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Date & Time:</span></b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'> Thursday, Dec 3rd, 2015, 2:00 PM<o:p></o:p></span></p><p class=MsoNormal style='text-autospace:none'><b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Venue:</span></b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'> Industrial Engineering Conference Room<o:p></o:p></span></p><p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Engineering Building 2, E214<o:p></o:p></span></p><p class=MsoNormal style='text-autospace:none'><b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Abstract:<o:p></o:p></span></b></p><p class=MsoNormal style='text-autospace:none'><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>The goal of radiation therapy is to maximize tumor cell kills while minimizing toxic effects on surrounding healthy tissues. This research addresses the treatment parameter uncertainty issue that can compromise the treatment quality and the biological effectiveness of radiation when using proton based radiation therapy. First, an automatic approach is proposed to satisfy clinical treatment goals, dose-volume constraints. Second, a comprehensive study was conducted with a thorough analysis to better understand how two of the well-known optimization models (LP and NLP) deal with uncertainties for intensity-modulated proton therapy (IMPT) using multiple cancer patient data. In practice, parameter uncertainties are unavoidable; hence, clinical constraint violations are allowed up to a certain degree. Therefore, the first chance constrained programming (CCP) framework is developed to handle set-up uncertainties in radiation treatment planning. Finally, the impact of incorporating variable relative biological effectiveness (RBE) in IMPT planning optimization is investigated. Unlike the current practice of using 1.1 multiplier to the photon-based counterpart, it is shown that the multiplier can vary greatly and contribute to unanticipated toxicities and recurrences.<o:p></o:p></span></p></div></body></html>